Publication:

1064-nm Nd:YAG laser as an antibiotic-sparing treatment option for inflammatory acne: a narrative review and evidence-informed practical treatment framework

Antibiotic stewardship has become an increasingly important consideration in acne management. Systemic antibiotics remain useful for selected patients with inflammatory acne, but repeated or prolonged exposure raises concerns regarding antimicrobial resistance, microbiome disruption, tolerability, and adherence. Non-antibiotic procedural approaches may therefore have a role as adjunctive or antibiotic-sparing options in carefully selected patients. To review the clinical rationale, evidence base, safety considerations, and practical integration of 1064-nm neodymium-doped yttrium aluminum garnet (Nd:YAG) laser therapy for inflammatory acne. A narrative PubMed-based review was conducted focusing on 1064-nm Nd:YAG laser therapy for active acne, antibiotic stewardship, standard acne therapy, device-based acne treatment, safety in skin of color, isotretinoin and energy-based devices, and competing technologies. Studies exclusively addressing acne scars, post-acne erythema, hidradenitis suppurativa, or acne keloidalis nuchae were excluded from the core evidence synthesis. Evidence for 1064-nm Nd:YAG laser therapy includes microsecond-domain 650-usec studies, millisecond long-pulsed protocols, Q-switched and carbon-assisted approaches, and comparative studies against other procedural modalities. A sham-controlled randomized trial supports 650-usec 1064-nm treatment, and prospective and retrospective studies report improvement across a range of acne severities and Fitzpatrick skin types. Comparative studies suggest benefit for inflammatory lesions, but protocols, outcomes, comparators, and follow-up periods remain heterogeneous. No study has definitively demonstrated reduced cumulative antibiotic exposure as a predefined endpoint. 1064-nm Nd:YAG laser therapy should not be presented as a replacement for guideline-based pharmacologic acne treatment. The most defensible role is as an adjunctive or potential antibiotic-sparing procedural option for selected patients with inflammatory acne. Future trials should prospectively measure antibiotic exposure, relapse, maintenance needs, patient-reported outcomes, and cost-effectiveness.